CLINICAL_TRIALS ClinicalTrials.gov record update

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03817515
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:45.420441+00:00
Published At: 2022-03-16T00:00:00+00:00
Record Updated At: 2022-03-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["PEComa, Malignant", "TSC1", "TSC2", "mTOR Pathway Abberation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-03-16"
protocolSection.identificationModule.nctId: "NCT03817515"
protocolSection.identificationModule.officialTitle: "Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation"
protocolSection.statusModule.overallStatus: "APPROVED_FOR_MARKETING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.